BeyondSpring Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. We are currently advancing the development of our lead asset Plinabulin, a novel cancer therapeutic, in a global Phase 3 trial in non-small-cell lung cancer (NSCLC) and initiating a pivotal global Phase 3 trial in prevention of docetaxel-induced neutropenia.
As a tubulin depolymerizing agent, Plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment:
1. Immune enhancing effects via dendritic cell maturation
2. Tumor cell apoptosis via activation of RAS-JNK pathway
3. Vascular disruptive effects
Given Plinabulin's potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications:
• Immuno-oncology, with immune checkpoint inhibitors in NSCLC
• CNS malignancies including glioblastoma (GBM)
• KRAS positive mutant cancers